1
Clinical Trials associated with REGN-13335A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN13335, a Platelet-Derived Growth Factor-B Antagonist, in Healthy Adult Participants
This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults.
The aim of the study is to see how safe and tolerable REGN13335 is in healthy volunteers.
The study is looking at several other research questions, including:
What side effects may happen from taking the study drug
How much study drug is present in the blood of study participants at different times
Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
100 Clinical Results associated with REGN-13335
100 Translational Medicine associated with REGN-13335
100 Patents (Medical) associated with REGN-13335
100 Deals associated with REGN-13335